Biosynthetic origins of the natural product, thiolactomycin: A unique and selective inhibitor of type II dissociated fatty acid synthases

被引:21
作者
Brown, MS
Akopiants, K
Resceck, DM
McArthur, HAI
McCormick, E
Reynolds, KA
机构
[1] Pfizer Inc, Bioproc R&D, Pfizer Global Res & Dev, Groton Labs, Groton, CT 06340 USA
[2] Virginia Commonwealth Univ, Sch Pharm, Dept Med Chem, Richmond, VA 23219 USA
关键词
D O I
10.1021/ja034540i
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Thiolactomycin (TLM), a natural product produced by both Nocardia and Streptomyces spp., is a potent and highly selective inhibitor of the type II dissociated fatty acid synthases of plants and bacteria. The unique mode of action of TLM and its low toxicity make it an attractive compound for development of new antimicrobial agents. In this study, incorporationstudies with 13C-labeled precursors demonstrate that TLM is derived from one acetate-derived starter unit and three methylmalonate-derived extender units. The unusual thiolactone represented by TLM represents a novel class of polyketide-derived antibiotics in which an unusual cyclization process, which terminates the biosynthetic pathway, involves incorporation of a sulfur atom from l-cysteine. Manipulation of this pathway through techniques such a combinatorial biosynthesis and mutasynthesis may provide a new route for economically viable production of useful TLM analogues. Copyright © 2003 American Chemical Society.
引用
收藏
页码:10166 / 10167
页数:2
相关论文
共 28 条
[11]   Role of crotonyl coenzyme A reductase in determining the ratio of polyketides monensin A and monensin B produced by Streptomyces cinnamonensis [J].
Liu, HB ;
Reynolds, KA .
JOURNAL OF BACTERIOLOGY, 1999, 181 (21) :6806-6813
[12]   Precursor supply for polyketide biosynthesis: The role of crotonyl-CoA reductase [J].
Liu, HB ;
Reynolds, KA .
METABOLIC ENGINEERING, 2001, 3 (01) :40-48
[13]   LL-E19085-ALPHA, A NOVEL ANTIBIOTIC FROM MICROMONOSPORA-CITREA - TAXONOMY, FERMENTATION AND BIOLOGICAL-ACTIVITY [J].
MAIESE, WM ;
LECHEVALIER, MP ;
LECHEVALIER, HA ;
KORSHALLA, J ;
GOODMAN, J ;
WILDEY, MJ ;
KUCK, N ;
GREENSTEIN, M .
JOURNAL OF ANTIBIOTICS, 1989, 42 (06) :846-851
[14]   A flexible route to (5R)-thiolactomycin, a naturally occurring inhibitor of fatty acid synthesis [J].
McFadden, JM ;
Frehywot, GL ;
Townsend, CA .
ORGANIC LETTERS, 2002, 4 (22) :3859-3862
[15]   THIOLACTOMYCIN, A NEW ANTIBIOTIC .4. BIOLOGICAL PROPERTIES AND CHEMOTHERAPEUTIC ACTIVITY IN MICE [J].
MIYAKAWA, S ;
SUZUKI, K ;
NOTO, T ;
HARADA, Y ;
OKAZAKI, H .
JOURNAL OF ANTIBIOTICS, 1982, 35 (04) :411-419
[16]   EFFECT OF THIOLACTOMYCIN ON THE INDIVIDUAL ENZYMES OF THE FATTY-ACID SYNTHASE SYSTEM IN ESCHERICHIA-COLI [J].
NISHIDA, I ;
KAWAGUCHI, A ;
YAMADA, M .
JOURNAL OF BIOCHEMISTRY, 1986, 99 (05) :1447-1454
[17]   THIOLACTOMYCIN, A NEW ANTIBIOTIC .3. INVITRO ANTIBACTERIAL ACTIVITY [J].
NOTO, T ;
MIYAKAWA, S ;
OISHI, H ;
ENDO, H ;
OKAZAKI, H .
JOURNAL OF ANTIBIOTICS, 1982, 35 (04) :401-410
[18]   THIOLACTOMYCIN, A NEW ANTIBIOTIC .1. TAXONOMY OF THE PRODUCING ORGANISM, FERMENTATION AND BIOLOGICAL PROPERTIES [J].
OISHI, H ;
NOTO, T ;
SASAKI, H ;
SUZUKI, K ;
HAYASHI, T ;
OKAZAKI, H ;
ANDO, K ;
SAWADA, M .
JOURNAL OF ANTIBIOTICS, 1982, 35 (04) :391-395
[19]   Bacterial fatty-acid biosynthesis: a genomics-driven target for antibacterial drug discovery [J].
Payne, DJ ;
Warren, PV ;
Holmes, DJ ;
Ji, YD ;
Lonsdale, JT .
DRUG DISCOVERY TODAY, 2001, 6 (10) :537-544
[20]   Inhibition of β-ketoacyl-acyl carrier protein syntheses by thiolactomycin and cerulenin -: Structure and mechanism [J].
Price, AC ;
Choi, KH ;
Heath, RJ ;
Li, ZM ;
White, SW ;
Rock, CO .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (09) :6551-6559